Form 8-K · Current Report · Filed 2025-02-18
Halozyme Therapeutics Reports Strong 2024 Financial Results and Reiterates 2025 Guidance
Halozyme Therapeutics, Inc. reported its financial results for the fourth quarter and full year ended December 31, 2024, revealing record revenue of $1.015 billion for the full year and exceeding its financial guidance for royalty revenue, adjusted EBITDA, and non-GAAP diluted EPS. The company's fourth-quarter total revenue increased by 30% year-over-year (YOY) to $298 million, with royalty revenue increasing by 40% YOY to $170 million. Net income for the quarter rose 60% YOY to $137 million, while adjusted EBITDA increased by 61% YOY to $196 million. For the full year, net income increased by 58% YOY to $444 million, adjusted EBITDA rose by 48% YOY to $632 million, and non-GAAP diluted EPS increased by 53% YOY to $4.23. Halozyme also reiterated its 2025 financial guidance, expecting total revenue of $1.150 - $1.225 billion, adjusted EBITDA of $755 - $805 million, and non-GAAP diluted EPS of $4.95 - $5.35.
- Filer
- Halozyme Therapeutics Inc. HALO · NASDAQ
- Filed
- Accession
- 0001159036-25-000008
- CIK
- 0001159036
- Signal
- High impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Results of Operations and Financial Condition
Financial Statements and Exhibits
Market reaction
Close before filing
$58.29
Next session
-0.9%
Since filing
+89.1%
Latest close
$110.24
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from HALO reporting the same item, with the next session's move:
Exhibits (1)
About Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc. is a biopharmaceutical company that specializes in developing and commercializing treatments focused on enhanced subcutaneous drug delivery. The company's proprietary technology, ENHANZE, aims to improve the efficacy and convenience of existing therapies by facilitating faster drug absorption and reducing the need for intravenous administration. Halozyme partners with major pharmaceutical companies to integrate its technology with a variety of treatments, significantly impacting the oncology, immunology, and genetic disorder sectors. This collaboration model helps expand the reach of its technology across multiple therapeutic applications. Based in San Diego, California, Halozyme is noted for its innovative approach to drug delivery, contributing to the broader pharmaceutical industry's efforts to improve patient experiences and optimize medical outcomes. As a significant player in the biopharmaceutical landscape, Halozyme's advancements continue to drive interest and growth within the market, underscoring the vital role of drug delivery technology in modern medicine.
Never miss another HALO filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.